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Background:We conducted a modified phase I/II trial investigating
the incorporation of three-dimensional conformal thoracic radiation
therapy (TCRT) into the treatment paradigm of induction and
concurrent carboplatin and paclitaxel in patients with unresectable
stage IIIA/B non-small cell lung cancer.
Methods: Patients received 2 cycles of induction carboplatin (area
under the curve of 6) and paclitaxel (225 mg/m2) on days 1, and 22.
On day 43 concurrent TCRT and weekly 6 of carboplatin (area
under the curve  2) and paclitaxel (45 mg/m2) was initiated. The
TCRT dose was escalated from 60 to 74 Gy in 4 cohorts (60, 66, 70,
and 74 Gy), and the 74 Gy cohort was expanded into a phase II trial.
Results: Sixty-two patients were enrolled; the median age 57 years
(range, 36–82), 39 were male (63%), 61 (98%) had a performance
status of 0 or 1, 28 (45%) had stage IIIA disease, 21 (34%) had5%
weight loss, and the median forced expiratory volume 1 2.10 liters
(range, 1.02–3.75). With a median follow-up for survivors of ap-
proximately 9 years (range, 7–11 years) the median progression-free
survival, time to tumor progression, and overall survival (OS) (with
95% confidence intervals) were 10 (8.5–17), 15 (9–50), and 25
months (18–37), respectively. The 5-year progression-free survival
and OS rates were 21% (12–32%) and 27% (17–39%), respectively.
The 10-year OS rate was 14% (7–25%).
Conclusion: The long term survival rate compares favorably to
other treatment approaches for stage III non-small cell lung cancer.
Key Words: Locally advanced non-small cell lung cancer, Com-
bined modality therapy, Paclitaxel, Carboplatin, Conformal thoracic
therapy, High dose.
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Lung cancer is the leading cause of cancer death in theUnited States, and it is estimated that in 2008 more
patients will die of lung cancer than prostate, colorectal,
and breast cancer combined.1 Non-small cell lung cancer
(NSCLC) accounts for 85% of the cases of lung cancer and
approximately 30% of patients will present with stage III
disease.2,3 The majority of patients who present with stage III
disease will not be candidates for surgical resection and the
standard of care for patients with a preserved performance
status (PS) is a combination of chemotherapy and radiother-
apy.4 Phase III trials have revealed treatment with the con-
current systemic dose chemotherapy and radiation therapy
yields an improved survival in comparison to sequential
chemotherapy and radiotherapy.5,6 Treatment with low dose
chemotherapy concurrent with radiation therapy has demon-
strated superior survival to radiotherapy alone, and improve-
ment in local control could result in improved overall survi-
val.7 Thus, most treatment paradigms for patients with
unresectable stage III disease include a combination of sys-
temic dose chemotherapy to prevent the development of
distant metastatic disease and concurrent chemoradiotherapy
to obtain local control. Unfortunately, the majority of the
patients experience local and/or distant disease progression.
The current standard dose of thoracic radiation therapy
(TRT) for inoperable lung was established by Radiation
Therapy Oncology Group (RTOG) trial 7301.8 Patients with
inoperable or unresectable stage III NSCLC who were en-
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rolled on this trial were randomized to 4 treatment arms: 40
Gy split course treatment (20 Gy in 5 fractions in 1 week, 2
weeks rest, and an additional 20 Gy in 5 fractions in 1 week),
or 40, 50, 60 Gy continuous course over 5 weeks. Patients on
the 50 and 60 Gy treatment arm had better tumor response
and a lower rate of intrathoracic recurrence (determined by
serial chest radiographs) than the lower dose arms, and based
on RTOG trial 7301 alone the dose of 60 Gy was established
as the current standard. This trial used 2-dimensional (2-D)
treatment planning where the tumor volume is defined on
radiographs which limited the accuracy of the tumor targeting
and increased the radiation exposure to organs within the
radiation field. Furthermore, this dose of TRT is inade-
quate to eradicate the intrathoracic disease in NSCLC. The
1-year local control rate observed on a phase III trial of
TRT alone (65 Gy) versus chemotherapy before and after
TRT (65 Gy) was 17% and 15%, respectively when pa-
tients underwent bronchoscopic evaluation for persistent
disease.9 In the interval since the RTOG trial 7301 was
performed there has been the development of modern
chemotherapy and three-dimensional thoracic conformal
radiation therapy (three-dimensional TCRT).
At the University of North Carolina we performed a
modified phase I/II trial investigating the incorporation of
dose escalation of three-dimensional TCRT into the treatment
paradigm of induction chemotherapy with concurrent chemo-
therapy. The modified phase I component of the trial estab-
lished the ability to escalate the dose of three-dimensional
TCRT,10 and the 74 Gy cohort of the study was expanded to
further assess the feasibility, toxicity, and clinical outcomes
of patients at this higher dose level.11 The hypothesis was that
improved tumor targeting and higher TRT dose was possible
with three-dimensional TCRT and would result in better
clinical outcomes. The median survival observed on the
initial publication was 26 months, and the median follow-up
for survival was 31 months (range, 17–54 months).11 How-
ever, the higher TRT may have delayed disease progression
without obtaining long term disease control; poor control of
systemic disease could have led to distant metastases, or the
development of isolated brain metastases could have limited
the long term survival of patients. We report the long term
follow-up of this trial.
PATIENTS AND METHODS
Eligibility Criteria
Patients eligible for this trial were required to have a
cytologic or histologic diagnosis of stage IIIA or IIIB disease
as defined by the 1986 staging system12 and be deemed
appropriate candidates for combined modality therapy. Pa-
tients with T3N0–1 disease on the basis of chest wall inva-
sion were excluded but all other patients with T3N0–1
disease were eligible.13 All patients were reviewed by a
thoracic radiologist, pulmonologist, thoracic surgeon, radia-
tion oncologist, and medical oncologist. Initial staging con-
sisted of a chest radiograph and a staging chest computed
tomography (CT) scan which included full visualization of
the liver and adrenal glands. Radionuclide bone scans were
required as was either a CT or magnetic resonance imaging
scan of the brain. Patients with supraclavicular adenopathy,
superior sulcus tumors, or pleural effusion were excluded.
Patients were required to have Eastern Cooperative Oncology
Group PS of 2 and could not have received prior chemo-
therapy or radiotherapy to the chest. Other required parame-
ters were as follows: absolute neutrophil count (ANC)
1500/mm3, platelet count100,000/mm3, serum creatinine
1.6 mg/dl or Cockcroft calculated creatinine clearance 40
ml/min, serum bilirubin 1.5 times upper limit of institu-
tional normal, serum aspartate aminotransferase and alanine
aminotransferase 2.5 times upper limit of institutional nor-
mal. Pulmonary function tests were required to document a
forced expiratory volume 1 (FEV-1) second of 800 ml. Of
note, there was no exclusion criteria related to weight loss.
Patients with a prior malignancy who were disease free 5
years were excluded (except carcinoma in situ of the cervix or
breast and nonmelanomatous skin cancer). Patients under-
went a bronchoscopy, mediastinoscopy, or transthoracic fine-
needle aspiration for diagnosis and staging as clinically indi-
cated. This trial was approved by the Protocol Review
Committee of the Lineberger Comprehensive Cancer Center
(LCCC) and the Institutional Review Board of the University
of North Carolina School of Medicine and Carolinas medical
center and was labeled LCCC 9603. All patients provided
informed consent before enrollment on this trial.
Treatment Administration
Chemotherapy
The treatment plan (Table 1) consisted of 2 cycles of
carboplatin area under the curve (AUC) 6 using the Calvert
equation14 and paclitaxel 225 mg/m2 (infused over 3 hours)
on days 1 and 22. Standard premedications for paclitaxel
(dexamethasone 20 mg intravenously [IV], ranitidine 50 mg
IV, and diphenhydramine 50 IV) were all given 30 minutes
before the paclitaxel infusions. On day 43 patients received
carboplatin AUC  2 and paclitaxel 45 mg/m2 (infused over
3 hours) weekly for 6 consecutive weeks. Standard paclitaxel
premedications were used with the weekly paclitaxel infu-
sions. Treatment on days 22 and 43 required an ANC1500/
mm3 and a platelet count of 100,000/mm3. During the
weekly therapy with TCRT a complete blood count was
monitored weekly, and the following adjustments were made
based on the complete blood count on the day of treatment:
for patients with an ANC1000/mm3 and75,000/mm3 the
carboplatin and paclitaxel doses remained AUC  2 and 45
mg/m2, respectively; for patients with ANC 500 to 999/mm3
or platelet count 50,000 to 74,000/mm3 the carboplatin and
paclitaxel doses were AUC  1 and 45 mg/m2, respectively;
and for patients with an ANC 500/mm3 and platelets
49,000/mm3 both carboplatin and paclitaxel were omitted.
TCRT
TCRT was initiated on day 43 with concurrent weekly
carboplatin and paclitaxel. Patients underwent a planning CT
scan after the second cycle of induction chemotherapy. De-
tails of the TCRT treatment planning have been published
previously.15 The lungs, esophagus, heart (left ventricle),
spinal cord, primary tumor, and radiographically positive
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lymph nodes were contoured. The prechemotherapy CT scan
then was registered spatially with the planning CT scan, and
the initial treatment was designed from it. The macroscopic
tumor volume (GTV) included the primary tumor and any
radiographically positive lymph nodes (all lymph nodes1.0
cm). The clinical target volume (CTV) included the GTV, the
entire uninvolved mediastinum, and 1.0 to 2.0 cm margin
around the GTV; then 50 Gy was delivered to the prechemo-
therapy CTV. Respiratory variation (planning target volume)
was taken into account only in that the inferior and superior
margins were usually extended to 2.0 cm. The boost volumes
included only the GTV and a 1.0 to 2.0 cm margin. The
treatment was given with a standard daily fractionation of 2.0
Gy per fraction 5 days a week. All quoted doses have
incorporated inhomogeneity corrections. Patients were
treated supine with the arms over the head but were not
immobilized otherwise, and port films of all fields were taken
at least once a week. The quoted doses are at the isocenter,
but variations over a 3D expanded CTV (1.0 cm) were within
5%. Radiation fields tended to follow standard practice using
anterioroposterior-posterioroanterior to spinal cord tolerance
and then obliques. In some patients, nonaxial fields were used
when they would significantly reduce the volume of the
normal lung treated. Radiation plans were developed from
historic experience and were not inverse planned. The spinal
cord dose was limited to 50 Gy anywhere within the cord,
including the dose under the blocks, the total left ventricle
dose was limited to 40 Gy, and the maximal dose to the
brachial plexus was kept to 66 Gy. While not specifically
required the length of the esophagus receiving full dose
radiation was kept as short as possible. When data on the
association between pneumonitis rates and the dose-volume
histograms became available16 attempts were made to limit
the lung volume receiving 20 Gy (V20) to 35%.
Patient Evaluation and Follow-Up
All patients had a CT scan performed 2 months after the
completion of TCRT. Routine clinical evaluation with a chest
radiograph was every 2 months for the first year, then every
3 months for 1 year, and then after 2 years every 6 months,
and then after 5 years patients were evaluated annually. If
patients had signs on physical examination (e.g., palpable
lymphadenopathy) or symptoms concerning for disease pro-
gression, they underwent the additional testing including
repeat CT scans of the chest/abdomen, imaging of the brain
and bone scans as clinically indicated.
Statistical Design
The primary objective of the modified phase I part of
the trial was to determine if the dose of TCRT could be
escalated from 60 to 74 Gy when delivered with concurrent
carboplatin and paclitaxel. The Cancer and Leukemia Group
B (CALGB) Expanded Toxicity Criteria were used to assess
toxicity on this study with the exception of the grading of
acute esophageal toxicity for which the RTOG grading sys-
tem was used. Once dose escalation to 74 Gy was completed
additional patients were enrolled at that dose level as the
phase II portion of the trial. The decision to expand the 74 Gy
cohort to a phase II trial and not investigate further dose
escalation was part of the initial trial design.10 This trial
design was employed to obtain additional information about
the efficacy of high-dose TCRT before pursuing further dose
escalation.10 A Simon two-stage minimax design was used
for the phase II portion of the trial.17 The six evaluable
patients from the phase I trial were included in the first stage
of the phase II trial. Details of the modified phase I and II
study design have been published previously.10,11
Statistical Methods
The Kaplan-Meier (or product limit) method was used
to estimate the three ‘time to event’ functions of: time to
tumor progression (TTP), progression free survival (PFS),
and overall survival (OS). TTP has been defined as the time
from the date of diagnosis until the date of disease progres-
sion (the event) or date of death or last contact (death
censored). PFS has been defined as the time from the date of
the diagnosis to the date of disease progression or death (two
events, whichever occurred first) or the date of last contact.
The date of progression has been defined as the documented
date of either pathologic confirmation of disease progression,
or the date when radiologic exams determined disease pro-
gression. OS has been defined as the time from the date of the
diagnosis to the date of death (the event) or the date of last
contact. Median follow-up time for survivors has been de-
fined as the median amount of the time that survivors have
been followed. Exact binomial confidence intervals have
TABLE 1. Patient Characteristics
Characteristic No. of Patients
Total no. of patients 62
Age (yr), median (range) 57 (36–82 yr)
Gender (male:female) 39:23
Race (white:non-white) 49:13
Stage (IIIA:IIIB) 28:34
Stage IIIA
T3N0–1 2
T1–2N2 19
T3N2 7
Stage IIIB
T1–2N3 11
T4N0 9
T4N2–3 14
Weight loss (5%:5%) 21:41
PS (0–1:2) 61:1
Histology (%)
Adenocarcinoma 36 (58%)
Squamous 23 (37%)
Other 3 (5%)
Pulmonary function tests,
median (range)
FEV1, l (range) 2.10 (1.02–3.75)
FVC, l (range) 3.27 (1.69–5.64)
DLCO (range)
(ml/min/mmHg)
14.5 (4.8–32.7)
FVC, forced vital capacity; FEV, forced expiratory volume; DLCO, diffusing
capacity of the lung for carbon monoxide.
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been calculated for the percentages of interest. Statistical
analyzes were performed using SAS statistical software,
Versions 9.1, SAS Institute Inc., Cary, NC.
RESULTS
Patient Characteristics
Between June 1996 and July 1999 62 patients were
enrolled on this trial (Table 2). The median age was 57 years
(range, 36–82). Thirty-nine (63%) were male, 28 (45%) had
stage IIIA and 34 (55%) had stage IIIB disease. Twenty-one
patients (34%) had 5% weight loss, and 61 patients (98%)
had a CALGB PS of 0 or 1 with only one patient having a PS
of 2. Adenocarcinoma was the most common histology
(58%) followed by squamous cell (37%) and non-small cell
lung cancer not otherwise specified (5%). The median FEV-1
was 2.10 L (range, 1.02–3.75). The median tumor volume
was 135 ml (range, 8–602 ml). Forty-eight of the 62 patients
initiated the concurrent chemoradiotherapy on day 43. The
reasons for not starting the protocol treatment on day 43
were: progressive disease (n  8, 13%) early death (n  2,
3%), and decline in PS due to intercurrent illness (n 1, 2%),
voluntary withdrawal (n  2, 3%) and paclitaxel hypersen-
sitivity reaction (n  1, 2%). The radiation dose patients
received on protocol during the phase I part of the trial were:
60 Gy (n  3, 5%), 64.6 (n  1, 2%), 66 Gy (n  5, 8%), 70
Gy (n  6, 10%); 39 patients were enrolled on the phase II
part of the trial, 32 patients initiated the concurrent chemo-
radiotherapy, and 31 (97%) completed treatment to 74 Gy.
Long Term Efficacy of Therapy
Patients were followed until death except those surviv-
ing who were followed from 7 to 11 years (median follow-up
9 years Table 3). Fifty-three of the patients have died; 33
patients died with evidence of disease progression, and
20 patients died without evidence of disease progression. Three
patients are alive with evidence of disease progression, and 6
patients are alive without evidence of disease progression.
The median survival time and the 5-year overall survival rate
observed were 25 months (95% confidence interval [CI],
18–37 months) and 27% (95% CI, 17–39%), respectively
(Figure 1). The 10-year survival rate was 14% (95% CI,
7–25%). The median PFS and 5-year progression-free sur-
vival rate observed were 10 months (95% CI, 8–17 months)
and 21% (95% CI, 12–32%), respectively (Figure 2). The
median TTP and 5-year tumor progression rate were 15
months (95% CI, 9–50 months) and 64% (95% CI, 51–77%),
respectively (Figure 3). Data were available to assess for
isolated brain relapse on 60 patients; 9 patients experienced
isolated brain metastatic disease and the rate of for isolated
brain metastatic disease was 15% (95% CI, 7–27%). Data to
FIGURE 1. Overall survival with 95% confidence intervals.
FIGURE 2. Progression-free survival with 95% confidence
intervals.
TABLE 2. Treatment Schema
Induction Chemotherapy Concurrent Chemotherapy
Carboplatin AUC  6 Carboplatin AUC  2 weekly  6
Paclitaxel 225 mg/m2 on days 1, 22 Paclitaxel 45 mg/m2 weekly  6
Thoracic conformal radiation therapy
Cohort Dose level
1 60 Gy
2 66 Gy
3 70 Gy
4 74 Gy
AUC, area under the curve.
TABLE 3. Long-Term Follow-Up of Efficacy of Combined
Modality Therapy
Parameter Median Time (95% CI) 5-yr Rate (95% CI)
Progression-free survival 10 (8.5–17) mo 21% (12–32%)
Time to tumor progression 15 (9–50) mo 64% (51–77%)
Overall survival 25 (18–37) mo 27% (17–39%)
CI, confidence interval.
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assess for radiographic evidence of local progression were
available on 53 patients and the rate of local progression was
34% (95% CI, 22–48%). Of note, one patient developed and
died as a result of a treatment related radiation-induced
sarcoma 8 years after completion of radiotherapy.18 No other
fatal treatment related complications were observed.
DISCUSSION
The median survival time of 25 months and 5-year
overall survival rate of 27% (95% CI, 17–39%) observed on
this trial are promising. The high TCRT may have contrib-
uted to the increased survival observed on this trial. The rate
of local progression as assessed by radiographic evaluation
was 34% (95% CI, 22–48%) but this rate probably would
have been higher if patients had undergone bronchoscopic
evaluation for tumor assessment and thus this rate should not
be compared with the local control rate observed on the trial
be Le Chevalier et al.9 The 10-year overall survival rate was
14% (95% CI, 7–25%). Unfortunately, there are limited data
to compare the 10-year overall survival rate observed on this
trial with other trials due to the fact that the majority of the
patients with stage III disease die of disease progression
within the first 3 years. Of note some patients died without
clinical or radiographic evidence of disease progression (n 
20) from causes other than their NSCLC. As a result of this
observation the TTP was calculated in addition to the pro-
gression-free survival. This revealed that the majority of the
patients who experienced disease progression did in the first
18 months. Nevertheless, the TTP should be interpreted
cautiously since there can be significant variability in the
investigation of disease progression depending on the clinical
circumstances, and the physician’s and patient’s preferences.
This parameter (or a similar parameter such as disease-
specific mortality) may be of value in future larger studies as
the prognosis of patients with stage III disease improves
the impact of deaths from comorbidities, subsequent ill-
nesses, or late treatment related adverse events may need
to be considered.
Although the current data are encouraging there is a
reasonable concern about patient selection bias. However, the
eligibility criteria in regard to PS, staging requirements, and
organ function were similar to other trials performed in this
patient population. In fact there was no exclusion criteria for
weight loss which is a known poor prognostic factor,19 and
the FEV-1 requirement was more lenient than other trials20,21
and similar to another trial.22 This trial was also performed
before the routine use of staging positron emission tomogra-
phy (PET) scan, and approximately 25% of patients with
stage III disease will have metastatic disease detected on PET
scan staging, and PET scan staging has been associated with
improved survival in stage III patients in comparison to
patients staged with conventional methods.23,24 The dose and
volume constraints of high dose three-dimensional TCRT in
the trial did restrict enrollment based on tumor volume,
anatomic location (e.g., superior sulcus tumors were excluded
due to the potential harm of high dose radiotherapy on the
brachial plexus), and to patients without supraclavicular
lymph node involvement.
The rate of isolated brain metastases observed on trial
was 15% (95% CI, 7–27%), and is similar to the rate ob-
served after combined modality therapy by other investiga-
tors. Of 422 patients treated on combined modality protocols
performed by the Southwest Oncology Group a total of 268
patients (64%) had experience disease progression; 54 (20%)
developed isolated brain metastases, 17 (6.5%) developed
metastases at the brain and other sites, 197 (63.5%) devel-
oped metastases at other sites.25 A similar review of 177
patients with stage III disease who were treated with com-
bined modality therapy revealed that 34% of patients recurred
in the brain as their first site of failure, and 40% of patients
developed brain metastases as some point in their course.26
To investigate the role of prophylactic cranial radiation (PCI)
in patients with stage III NSCLC the RTOG initiated a phase
III trial (RTOG 0214) of PCI versus observation after com-
pletion of definitive therapy for stage III NSCLC.27 Unfortu-
nately the trial closed early due to poor accrual, and the role
of PCI therapy in stage III NSCLC is unknown at this time.
The chemotherapy paradigm used in this trial may be
considered suboptimal by some investigators based on the
results of trials that have been completed and published since
the time this trial was initiated. The phase III trials that have
revealed a survival benefit to concurrent chemoradiotherapy
have used systemic dose cisplatin-based chemotherapy rather
than low dose carboplatin and paclitaxel therapy.5,6 There is
also evidence from the metastatic setting that cisplatin-based
treatments provide superior survival than carboplatin-based
therapies, but with greater toxicity.28,29 These data raises the
question of whether cisplatin is a better agent in NSCLC,
particularly when the intent of the treatment is curative.
Furthermore, phase III trials that have compared the treat-
ment strategy of induction chemotherapy followed by con-
current chemotherapy versus concurrent chemoradiotherapy
have not revealed a statistically significant survival benefit
with the addition of induction chemotherapy.19,30 It is possi-
FIGURE 3. Time to tumor progression with95% confidence
intervals.
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ble that modification of the chemotherapy platform or the
addition of a targeted agent may have greater efficacy pro-
vided that the combination had acceptable toxicity and did
not compromise the delivery of the high dose TCRT.
Other investigators have also performed trials that have
investigated dose escalation of TCRT in NSCLC. RTOG trial
0117 was a phase I/II trial that investigated dose escalation of
TCRT in combination with concurrent carboplatin and pac-
litaxel in patients with stage I-III NSCLC with a PS of 0–1
and 10% weight loss.31 The dose constraints employed on
this trial included: a V2030% and for the esophagus a mean
dose 34 Gy and V55 30%. The phase I part of the trial
enrolled 17 patients, and the maximum-tolerated dose of
TCRT with concurrent chemotherapy, was determined to be
74 Gy. The phase II portion of the trial is currently enrolling
patients.31 The North Central Cancer Treatment Group
(NCCTG) also performed a phase I/II trial that investigated
dose escalation of TCRT in combination with concurrent
carboplatin and paclitaxel in patients with unresectable stage
I–III NSCLC, a PS of 0–1, and weight loss 10%.32 This
trial employed the following dose constraints: no part of the
spinal cord could receive greater than 48 Gy, a V20 of40%,
the full circumference of esophagus could not receive 60
Gy, the entire brachial plexus could not receive 60 Gy, and
one-third the heart could not receive 60 Gy, two-thirds
could not receive50 Gy, and the entire heart could40 Gy.
The phase I portion of the trial included 15 patients and the
maximum-tolerated dose of TCRT with concurrent carbopla-
tin and paclitaxel was 74 Gy. The phase II portion of the trial
is currently enrolling patients.32 These trials provide addi-
tional evidence of the safety of TCRT to 74 Gy with concur-
rent carboplatin and paclitaxel.
Recently this treatment paradigm was investigated in
CALGB trial 30105. This trial was a two arm phase II trial
that investigated induction therapy with carboplatin with
either gemcitabine or paclitaxel for two cycles followed
bi-weekly gemcitabine (arm A) with concurrent TCRT or
weekly carboplatin and paclitaxel with concurrent TCRT (74
Gy) (arm B).33 The trial enrolled (n  69); arm A was closed
after 26 patients had been enrolled due to the fact that 3
patients experienced grade 5 pulmonary events and arm B
enrolled 43 patients. The median progression-free and me-
dian survival times observed on arm B were 14.9 months and
24.3 months (95% CI, 12.3–36.4), respectively. The median
survival time observed on this trial was higher than the
median survival time observed on the previous CALGB
trials, 9431 and 39801.19,34 The major therapeutic difference
between CALGB 30105 and LCCC 9603 and the other
CALGB trials was the higher total dose of 74 Gy.
Based on the safety and efficacy of our modified phase
I/II trial, CALGB trial 30105, and the safety data and pre-
liminary efficacy results of the phase I/II RTOG 0117 and the
NCCTG trials a phase III trial (RTOG 0617) comparing
TCRT at the standard dose of 60 Gy versus a higher dose of
74 Gy with concurrent chemotherapy was recently initiated.35
In this trial, patients will be treated with concurrent chemo-
therapy (weekly carboplatin AUC  2 and paclitaxel 45
mg/m2) in combination with TCRT. After completion of the
concurrent chemoradiotherapy, all patients will then be
treated with 2 cycles of systemic chemotherapy (carboplatin
AUC  6 and paclitaxel 200 mg/m2) every 3 weeks. This
randomized phase III trial, performed in cooperation by
CALGB, RTOG, and the NCCTG will provide additional
information about the efficacy, as well as acute and late
toxicities of high dose three-dimensional TCRT. Until the
results of this phase III trial are available the treatment
strategy of low dose concurrent carboplatin and paclitaxel
with high dose TCRT and systemic dose carboplatin and
paclitaxel should be considered investigational.
REFERENCES
1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer
J Clin 2008;58:71–96.
2. Yang P, Allen MS, Aubry MC, et al. Clinical features of 5,628 primary
lung cancer patients: experience at Mayo Clinic from 1997 to 2003.
Chest 2005;128:452–462.
3. Govindan R, Page N, Morgensztern D, et al. Changing epidemiology of
small-cell lung cancer in the United States over the last 30 years:
analysis of the surveillance, epidemiologic, and end results database.
J Clin Oncol 2006;24:4539–4544.
4. Pfister DG, Johnson DH, Azzoli CG, et al. American Society of Clinical
Oncology Treatment of Unresectable Non-Small Cell Lung Cancer
Guideline: update 2003. J Clin Oncol 2004;22:330–353.
5. Furuse K, for the West Japan Lung Cancer Group. Phase III study of
concurrent versus sequential thoracic radiotherapy in combination with
mitomycin, vindesine, and cisplatin in unresectable stage III non-small
cell lung cancer. J Clin Oncol 1999;17:2692–2699.
6. Curran WJ, Scott C, Langer C. Phase III comparison of sequential vs
concurrent chemoradiation for PTS with unresected stage III non-small
cell lung cancer (NSCLC): initial report of Radiation Therapy Oncology
Group (RTOG) 9410. Proc Am Soc Clin Oncol 2000;19:484a (abstract
1891).
7. Schaake-Koning C, van den Bogaert W, Dalesio O, et al. Effects of
concomitant cisplatin and radiotherapy on inoperable non-small-cell
lung cancer. N Engl J Med 1992;326:524–530.
8. Perez CA, Stanley K, Rubin P, et al. A prospective randomized study of
various irradiation doses and fractionation schedules in the treatment of
inoperable non-oat-cell carcinoma of the lung. Preliminary report by the
Radiation Therapy Oncology Group. Cancer 1980;45:2744–2753.
9. Le Chevalier T, Arrigada R, Quoix E, et al. Radiotherapy alone versus
combined chemotherapy and radiotherapy in non-resectable non-small
cell lung cancer: first analysis of randomized trial in 353 patients. J Natl
Cancer Inst 1991;83:417–423.
10. Socinski MA, Rosenman JG, Schell MJ, et al. Induction carboplatin/
paclitaxel followed by concurrent carboplatin/paclitaxel and dose-esca-
lating conformal thoracic radiation therapy in unresectable stage IIIA/B
non-small cell lung carcinoma: a modified Phase I trial. Cancer 2000;
89:534–542.
11. Socinski MA, Rosenman JG, Halle J, et al. Dose-escalating conformal
thoracic radiation therapy with induction and concurrent carboplatin/
paclitaxel in unresectable stage IIIA/B nonsmall cell lung carcinoma: a
modified phase I/II trial. Cancer 2001;92:1213–1223.
12. Beahrs O, Henson D, Hutter R, Myers M, (Eds.) Manual for staging of
cancer, 3rd Ed. Philadelphia: Lippincott, 1988.
13. Detterbeck FC, Socinski MA. IIB or not IIB: the current question in
staging non-small cell lung cancer. Chest 1997;112:229–234.
14. Calvert A, Newell D, Gumbrell L, O’Reilly S, Burnell M, Boxall F.
Carboplatin dosage: prospective evaluation of a simple formula based on
renal function. J Clin Oncol 1989;7:1748–1756.
15. Rosenman JG, Halle JS, Socinski MA, et al. High-dose conformal
radiotherapy for treatment of stage IIIA/IIIB non-small-cell lung cancer:
technical issues and results of a phase I/II trial. Int J Radiat Oncol Biol
Phys 2002;54:348–356.
16. Graham MV, Purdy JA, Emami B, et al. Clinical dose-volume histogram
analysis for pneumonitis after 3D treatment for non-small cell lung
cancer (NSCLC). Int J Radiat Oncol Biol Phys 1999;45:323–329.
Stinchcombe et al. Journal of Thoracic Oncology • Volume 3, Number 11, November 2008
Copyright © 2008 by the International Association for the Study of Lung Cancer1284
17. Simon R. Optimal two-stage designs for phase II clinical trials. Control
Clin Trials 1989;10:1–10.
18. Stinchcombe TE, Walters R, Khandani AH, Socinski MA. Radiation-
induced sarcoma after high-dose thoracic radiation therapy in non-small-
cell lung cancer. J Clin Oncol 2007;25:1621–1623.
19. Vokes EE, Herndon JE II, Kelley MJ, et al. Induction chemotherapy
followed by chemoradiotherapy compared with chemoradiotherapy
alone for regionally advanced unresectable stage III Non-small-cell lung
cancer: Cancer and Leukemia Group B. J Clin Oncol 2007;25:1698–
1704.
20. Gandara DR, Chansky K, Albain KS, et al. Consolidation docetaxel after
concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer:
phase II Southwest Oncology Group Study S9504. J Clin Oncol 2003;
21:2004–2010.
21. Kelly K, Chansky K, Gaspar LE, et al. Phase III trial of maintenance
gefitinib or placebo after concurrent chemoradiotherapy and docetaxel
consolidation in inoperable stage III non-small-cell lung cancer: SWOG
S0023. J Clin Oncol 2008;26:2450–2456.
22. Hanna NH, Neubauer M, Ansari R, et al. Phase III trial of cisplatin (P)
plus etoposide (E) plus concurrent chest radiation (XRT) with or without
consolidation docetaxel (D) in patients (pts) with inoperable stage III
non-small cell lung cancer (NSCLC): HOG LUN 01–24/USO-023.,
2007 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007;
2518S:abstract 7512.
23. Morgensztern D, Goodgame B, Baggstrom MQ, Gao F, Govindan R.
The effect of FDG-PET on the stage distribution of non-small cell lung
cancer. J Thorac Oncol 2008;3:135–139.
24. MacManus MP, Hicks RJ, Matthews JP, et al. High rate of detection of
unsuspected distant metastases by pet in apparent stage III non-small-
cell lung cancer: implications for radical radiation therapy. Int J Radiat
Oncol Biol Phys 2001;50:287–293.
25. Gaspar LE, Chansky K, Albain KS, et al. Time from treatment to
subsequent diagnosis of brain metastases in stage III non-small-cell lung
cancer: a retrospective review by the Southwest Oncology Group. J Clin
Oncol 2005;23:2955–2961.
26. Mamon HJ, Yeap BY, Janne PA, et al. High risk of brain metastases in
surgically staged IIIA non-small-cell lung cancer patients treated with
surgery, chemotherapy, and radiation. J Clin Oncol 2005;23:1530–1537.
27. Pugh TJ, Gaspar LE. Prophylactic cranial irradiation for patients with
lung cancer. Clin Lung Cancer 2007;8:365–368.
28. Hotta K, Matsuo K, Ueoka H, Kiura K, Tabata M, Tanimoto M.
Meta-analysis of randomized clinical trials comparing Cisplatin to Car-
boplatin in patients with advanced non-small-cell lung cancer. J Clin
Oncol 2004;22:3852–3859.
29. Ardizzoni A, Boni L, Tiseo M, et al. Cisplatin- versus carboplatin-based
chemotherapy in first-line treatment of advanced non-small-cell lung
cancer: an individual patient data meta-analysis. J Natl Cancer Inst
2007;99:847–857.
30. Kim M, Kim S, Choi E, et al. Induction chemotherapy followed by
concurrent chemoradiotherapy (CCRT) versus concurrent chemotherapy
(CCRT) alone for unresectable non-small cell lung cancer: randomized
phase III trial. J Thorac Oncol 2007;2:S308.
31. Bradley JD, Graham M, Suzanne S, et al. Phase I Results of RTOG
L-0117; a Phase I/II Dose Intensification Study Using 3DCRT and
Concurrent Chemotherapy for Patients with Inoperable NSCLC. J Clin
Oncol 2005 ASCO Annual Meeting Proceedings 2005;23(16S, Part I of
II June 1 Supplement):abstract 7063, 636s.
32. Schild SE, McGinnis WL, Graham D, et al. Results of a Phase I trial of
concurrent chemotherapy and escalating doses of radiation for unresect-
able non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2006;65:
1106–1111.
33. Socinski MA, Blackstock AW, Bogart JA, et al. Randomized phase II
trial of induction chemotherapy followed by concurrent chemotherapy
and dose-escalated thoracic conformal radiotherapy (74 Gy) in stage III
non-small-cell lung cancer: CALGB 30105. J Clin Oncol 2008;26:
2457–2463.
34. Vokes EE, Herndon JE II, Crawford J, et al. Randomized phase II study
of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction
chemotherapy followed by concomitant chemoradiotherapy for stage
IIIB non-small-cell lung cancer: cancer and leukemia group B study
9431. J Clin Oncol 2002;20:4191–4198.
35. RTOG 0617. Available at www.clinicaltrials.gov-assessed. Accessed
May 21, 2008.
Journal of Thoracic Oncology • Volume 3, Number 11, November 2008 Long-Term Follow-Up of a Phase I/II Trial
Copyright © 2008 by the International Association for the Study of Lung Cancer 1285
